Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chemotherapy induced-vomiting--a practical guide for prevention and therapy].

K Jordan1, W Voigt, H-J Schmoll

  • 1Klinik für Innere Medizin IV, Hämatologie/Onkologie, Martin-Luther-Universität Halle/Wittenberg, Ernst-Grube-Strasse 40, 06120 Halle/Salle. Karin.jordan@medizin.uni-halle.de

Deutsche Medizinische Wochenschrift (1946)
|August 18, 2006
PubMed
Summary

Chemotherapy-induced nausea and vomiting are distressing. New antiemetic therapies combining neurokinin-1-receptor-antagonists, 5-HT(3) receptor-antagonists, and steroids protect 70-90% of patients from emesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development.

ESMO open·2025
Same author

Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis.

ESMO open·2025
Same author

A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?

ESMO open·2025
Same author

Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

ESMO open·2024

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Context:

  • Nausea and vomiting are significant adverse effects of chemotherapy.
  • The severity of these side effects is linked to the emetogenic potential of chemotherapy drugs.

Purpose:

  • To describe recent advancements in antiemetic therapy.
  • To outline current guidelines for antiemetic prophylaxis.

Summary:

  • Modern antiemetic regimens, particularly those combining neurokinin-1-receptor-antagonists, 5-HT(3) receptor-antagonists, and steroids, are highly effective.
  • These combination therapies can protect 70-90% of patients undergoing highly emetogenic chemotherapy from nausea and vomiting.

Impact:

  • Improved patient quality of life during chemotherapy.

Related Experiment Videos

  • Enhanced adherence to necessary cancer treatments.
  • Reduced healthcare burden associated with managing chemotherapy side effects.